Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GLAXF) Leases (2019 - 2025)

Historic Leases for Gsk (GLAXF) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • Gsk's Leases fell 235.15% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 235.15%. This contributed to the annual value of $1.1 billion for FY2024, which is 721.1% down from last year.
  • Per Gsk's latest filing, its Leases stood at $1.1 billion for Q3 2025, which was down 235.15% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Leases ranged from a high of $1.2 billion in Q4 2023 and a low of $134.2 million during Q1 2022
  • Over the past 5 years, Gsk's median Leases value was $1.0 billion (recorded in 2025), while the average stood at $944.8 million.
  • Per our database at Business Quant, Gsk's Leases tumbled by 8769.78% in 2022 and then surged by 49424.14% in 2023.
  • Gsk's Leases (Quarter) stood at $997.5 million in 2021, then decreased by 19.22% to $805.8 million in 2022, then skyrocketed by 44.32% to $1.2 billion in 2023, then decreased by 6.63% to $1.1 billion in 2024, then decreased by 1.85% to $1.1 billion in 2025.
  • Its Leases was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.0 billion in Q1 2025.